Inventiva Welcomes Renée Aguiar-Lucander to Its Board of Directors
Inventiva, a clinical-stage biopharmaceutical company dedicated to treating metabolic dysfunction-associated steatohepatitis (MASH), has made an exciting announcement. The company recently appointed Renée Aguiar-Lucander to its Board of Directors. This decision came during the Company’s Annual General Meeting where shareholders overwhelmingly supported her addition.
Enhancing Strategic Leadership
Mark Pruzanski, Chairman of Inventiva, expressed enthusiasm regarding Renée's appointment. He stated, "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva’s journey. Her exceptional track record in our industry speaks for itself and will be key as we enter the final stages of clinical development for lanifibranor and prepare for its potential approval and launch." This reflects the strategic steps Inventiva is taking as they prepare for significant advancements in their lead asset, lanifibranor.
Renée Aguiar-Lucander's Vast Experience
In her own words, Renée shared her excitement about joining Inventiva’s Board: "I’m honored to have the opportunity to join Inventiva’s Board. With the NATiV3 Phase 3 trial fully enrolled, I look forward to working with the team to potentially bring lanifibranor to patients with MASH." Renée's background is impressive; she has recently served as the Chief Executive Officer of Hansa Biopharma and previously held a similar role at Calliditas Therapeutics. Her leadership was instrumental in transforming Calliditas from a small biotech into a major player in rare diseases. This experience will undoubtedly be beneficial to Inventiva.
Achievements and Contributions
At Calliditas, Renée led significant advancements, including the FDA's approval of the first-ever treatment for IgA nephropathy, named TARPEYO. Her successful navigation through the complexities of biotech leadership culminated in the company's acquisition by Asahi Kasei for $1.1 billion.
Inventiva’s Ongoing Commitment to Innovation
Established as a public company, Inventiva continues to focus on developing oral therapies aimed at tackling significant medical needs like MASH. The company is conducting the NATiV3 pivotal Phase 3 clinical trial to explore lanifibranor's effectiveness in treating adult patients with this chronic liver condition. This step exemplifies Inventiva's commitment to innovation and meeting the needs of patients suffering from liver diseases.
Current Research Focus
Lanifibranor, a novel pan-PPAR agonist, is expected to make a significant impact in treating patients with MASH. By enrolling patients in the NATiV3 trial, Inventiva is taking necessary steps toward regaining momentum in its clinical programs, particularly with an effective therapy that can change the lives of many individuals.
Looking Ahead
Inventiva is keen on leveraging its recent board addition's experience to navigate the complexities of clinical trials and regulatory approvals. The strategic appointment of Renée reflects the Company's anticipation of future challenges while positioning itself as a leader in its field.
Frequently Asked Questions
Who is Renée Aguiar-Lucander?
Renée Aguiar-Lucander is the newly appointed member of Inventiva's Board of Directors, bringing extensive experience from her previous CEO roles in biotech companies.
What is Inventiva's main focus?
Inventiva specializes in developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other unmet medical needs.
What is the NATiV3 trial?
The NATiV3 trial is a pivotal Phase 3 clinical study evaluating the efficacy of lanifibranor in treating adult patients with MASH.
What previous achievements does Renée have?
Renée successfully led Calliditas Therapeutics to an FDA approval for IgA nephropathy treatment and its acquisition by Asahi Kasei.
How does Inventiva plan to advance its therapies?
With the addition of experienced leaders like Renée, Inventiva aims to enhance its clinical development strategies and seek regulatory approvals for its therapies.
